Recursion is Granted EU Orphan Drug Designation for REC-4881

SALT LAKE CITY, July 21, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the

Related Keywords

Germany , Salt Lake City , Utah , United States , United Kingdom , Italy , Toronto , Ontario , Canada , France , Spain , Meredith Brown Tuttle , Exchange Commission , Linkedin , Regulatory Affairs , Twitter , European Union , European Commission , Drug Administration , Recursion Orphan Drug Designation , Vice President , Orphan Drug Designation , Orphan Drug , Fast Track , Recursion Operating System , Recursion Data , Recursion Map , San Francisco Bay , Securities Litigation Reform Act , Recursion , Granted , Orphan , Drug , Resignation , 1881 , Potential , Treatment , Familial , Denomatous , Olyposis ,